Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Case Report

Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation

Authors: Osamu Yamazaki, Yoshifumi Ubara, Tatsuya Suwabe, Shohei Nakanishi, Junichi Hoshino, Naoki Sawa, Noriko Hayami, Masayuki Yamanouchi, Fumi Takemoto, Takaichi Kenmei, Kazuhiro Masuoka, Kenichi Oohashi

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

We report a 58-year-old Japanese man with primary systemic AL amyloidosis who achieved disappearance of proteinuria including Bence-Jones protein (λ-type) after two courses of VAD therapy (vincristine, doxorubicin, and dexamethasone) and subsequent high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. Because this patient did not have any apparent amyloidosis-related heart or liver damage and met all of the eligibility criteria for this therapy, this treatment was performed. Both proteinuria and M-protein disappeared completely, and he is doing well clinically at 19 months after treatment. However, amyloid deposits were still found in the kidneys, including the glomeruli and tubulointerstitium, when renal biopsy was done at 8 months after treatment. In the future, we may reach a time when clinical remission corresponds to histological remission.
Literature
1.
go back to reference Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMed Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMed
2.
go back to reference Kyle RA, Gertz MA, Greipp PF, Witzig TE, Lust JA, Lacy MO, et al. A trial of three regimens of primary amyloidosis alone, melphalan, prednisolone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.CrossRefPubMed Kyle RA, Gertz MA, Greipp PF, Witzig TE, Lust JA, Lacy MO, et al. A trial of three regimens of primary amyloidosis alone, melphalan, prednisolone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.CrossRefPubMed
3.
go back to reference Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–82.CrossRefPubMed Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–82.CrossRefPubMed
4.
go back to reference Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662–70.PubMed Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662–70.PubMed
5.
go back to reference Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–93.CrossRefPubMed Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–93.CrossRefPubMed
6.
go back to reference Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766–9.CrossRefPubMed Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766–9.CrossRefPubMed
7.
go back to reference Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998;78(6):774–6.CrossRefPubMedPubMedCentral Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998;78(6):774–6.CrossRefPubMedPubMedCentral
8.
go back to reference Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42(1):72–7.CrossRefPubMed Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42(1):72–7.CrossRefPubMed
9.
go back to reference Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11(4):245–56.CrossRefPubMed Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11(4):245–56.CrossRefPubMed
Metadata
Title
Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
Authors
Osamu Yamazaki
Yoshifumi Ubara
Tatsuya Suwabe
Shohei Nakanishi
Junichi Hoshino
Naoki Sawa
Noriko Hayami
Masayuki Yamanouchi
Fumi Takemoto
Takaichi Kenmei
Kazuhiro Masuoka
Kenichi Oohashi
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0198-y

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.